Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015000LC2
Tue, 06.02.2024
Mainz BioMed N.V.
MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY
Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients.
BERKELEY, US – MAINZ, Germany – February 6, 2024 — Mainz [ … ]
Thu, 11.01.2024
Mainz BioMed N.V.
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
BERKELEY, US – MAINZ, Germany – January 11, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 1 [ … ]
Tue, 09.01.2024
Mainz BioMed N.V.
Mainz Biomed Provides Year-End Corporate Review 2023
European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition
ReconAAsense designed to evaluate gold standard at home colorectal cancer screening test and is on track to commence enr [ … ]
Tue, 19.12.2023
Mainz BioMed N.V.
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and Crimmitschau, in Q1 2024.
BERKELE [ … ]
Tue, 12.12.2023
Mainz BioMed N.V.
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
BERKELEY, US – MAINZ, Germany – DECEMBER 12, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Po [ … ]
Tue, 05.12.2023
Mainz BioMed N.V.
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82%
Results Exceed those from the Company’s European ColoFuture Clinical Study of the Same Design
[ … ]
Wed, 29.11.2023
Mainz BioMed N.V.
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
BERKELEY, US – MAINZ, Germany – NOVEMBER 29, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its presenta [ … ]
Mon, 20.11.2023
Mainz BioMed N.V.
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
BERKELEY, US – MAINZ, Germany – November 20, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that Guido Baechler, Chief Executive Officer and Bil [ … ]
Thu, 16.11.2023
Mainz BioMed N.V.
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023
ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 8 [ … ]
Wed, 15.11.2023
Mainz BioMed N.V.
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
BERKELEY, US – MAINZ, Germany – NOVEMBER 15, 2023 — Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced registered d [ … ]